Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1

Steven D. Rhodes, Feng-Chun Yang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene. NF1 encodes the protein neurofibromin, which functions to negatively regulate Ras-activity. Approximately 50 % of NF1 patients develop osteopenia or osteoporosis, resulting in significantly increased rates of long-bone fracture and morbidity. While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggest that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models delineating a critical role for hematopoietic compartment, myeloid progenitors of NF1 (Nf1) haploinsufficient and their progeny-osteoclasts, in the pathogenesis of NF1 associated osteopenia/osteoporosis and discuss putative targets for future therapeutics.

Original languageEnglish (US)
Pages (from-to)10-15
Number of pages6
JournalCurrent Osteoporosis Reports
Volume14
Issue number1
DOIs
StatePublished - Feb 1 2016

Fingerprint

Neurofibromatosis 1
Osteoporosis
Neurofibromin 1
Metabolic Bone Diseases
Osteoclasts
Haploinsufficiency
Inborn Genetic Diseases
Bone Fractures
Tumor Suppressor Genes
Osteoblasts
Morbidity
Bone and Bones
Mutation

Keywords

  • Neurofibromatosis type 1
  • Osteoclasts
  • Osteoporosis
  • Therapies

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1. / Rhodes, Steven D.; Yang, Feng-Chun.

In: Current Osteoporosis Reports, Vol. 14, No. 1, 01.02.2016, p. 10-15.

Research output: Contribution to journalArticle

@article{a28fc1043ed74ac598d91693c189c52d,
title = "Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1",
abstract = "Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene. NF1 encodes the protein neurofibromin, which functions to negatively regulate Ras-activity. Approximately 50 {\%} of NF1 patients develop osteopenia or osteoporosis, resulting in significantly increased rates of long-bone fracture and morbidity. While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggest that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models delineating a critical role for hematopoietic compartment, myeloid progenitors of NF1 (Nf1) haploinsufficient and their progeny-osteoclasts, in the pathogenesis of NF1 associated osteopenia/osteoporosis and discuss putative targets for future therapeutics.",
keywords = "Neurofibromatosis type 1, Osteoclasts, Osteoporosis, Therapies",
author = "Rhodes, {Steven D.} and Feng-Chun Yang",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s11914-016-0298-z",
language = "English (US)",
volume = "14",
pages = "10--15",
journal = "Current Osteoporosis Reports",
issn = "1544-1873",
publisher = "Current Science, Inc.",
number = "1",

}

TY - JOUR

T1 - Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1

AU - Rhodes, Steven D.

AU - Yang, Feng-Chun

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene. NF1 encodes the protein neurofibromin, which functions to negatively regulate Ras-activity. Approximately 50 % of NF1 patients develop osteopenia or osteoporosis, resulting in significantly increased rates of long-bone fracture and morbidity. While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggest that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models delineating a critical role for hematopoietic compartment, myeloid progenitors of NF1 (Nf1) haploinsufficient and their progeny-osteoclasts, in the pathogenesis of NF1 associated osteopenia/osteoporosis and discuss putative targets for future therapeutics.

AB - Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is a common autosomal dominant genetic disorder affecting approximately 1 in 3000 individuals worldwide. NF1 results from heritable or spontaneous mutations of the NF1 tumor suppressor gene. NF1 encodes the protein neurofibromin, which functions to negatively regulate Ras-activity. Approximately 50 % of NF1 patients develop osteopenia or osteoporosis, resulting in significantly increased rates of long-bone fracture and morbidity. While defective osteoblast bone anabolism has been implicated as a central factor in the pathogenesis of NF1 associated skeletal deficits, recent data suggest that NF1 (Nf1) haploinsufficiency within the hematopoietic compartment, particularly in osteoclasts and myeloid progenitors, plays a pivotal role in engendering NF1 osseous manifestations. In this chapter, we review the latest data from clinical studies and murine models delineating a critical role for hematopoietic compartment, myeloid progenitors of NF1 (Nf1) haploinsufficient and their progeny-osteoclasts, in the pathogenesis of NF1 associated osteopenia/osteoporosis and discuss putative targets for future therapeutics.

KW - Neurofibromatosis type 1

KW - Osteoclasts

KW - Osteoporosis

KW - Therapies

UR - http://www.scopus.com/inward/record.url?scp=84960372301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960372301&partnerID=8YFLogxK

U2 - 10.1007/s11914-016-0298-z

DO - 10.1007/s11914-016-0298-z

M3 - Article

C2 - 26932441

AN - SCOPUS:84960372301

VL - 14

SP - 10

EP - 15

JO - Current Osteoporosis Reports

JF - Current Osteoporosis Reports

SN - 1544-1873

IS - 1

ER -